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Abstract
Background: Microparticles (MPs) are vesicles released from plasma membrane upon cell activation and during apoptosis.
Human T lymphocytes undergoing activation and apoptosis generate MPs bearing morphogen Shh (MPs
Shh+) that are able
to regulate in vitro angiogenesis.
Methodology/Principal Findings: Here, we investigated the ability of MPs
Shh+ to modulate neovascularization in a model of
mouse hind limb ischemia. Mice were treated in vivo for 21 days with vehicle, MPs
Shh+, MPs
Shh+ plus cyclopamine or
cyclopamine alone, an inhibitor of Shh signalling. Laser doppler analysis revealed that the recovery of the blood flow was
1.4 fold higher in MPs
Shh+-treated mice than in controls, and this was associated with an activation of Shh pathway in
muscles and an increase in NO production in both aorta and muscles. MPs
Shh+-mediated effects on flow recovery and NO
production were completely prevented when Shh signalling was inhibited by cyclopamine. In aorta, MPs
Shh+ increased
activation of eNOS/Akt pathway, and VEGF expression, being inhibited by cyclopamine. By contrast, in muscles, MPs
Shh+
enhanced eNOS expression and phosphorylation and decreased caveolin-1 expression, but cyclopamine prevented only the
effects of MPs
Shh+ on eNOS pathway. Quantitative RT-PCR revealed that MPs
Shh+ treatment increased FGF5, FGF2, VEGF A
and C mRNA levels and decreased those of a5-integrin, FLT-4, HGF, IGF-1, KDR, MCP-1, MT1-MMP, MMP-2, TGFb1, TGFb2,
TSP-1 and VCAM-1, in ischemic muscles.
Conclusions/Significance: These findings suggest that MPs
Shh+ may contribute to reparative neovascularization after
ischemic injury by regulating NO pathway and genes involved in angiogenesis.
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Introduction
Microparticles (MPs) are small plasma membrane fragments
shed by cells after blebbing due to activation and/or apoptosis.
They play an important role in cell to cell communication because
of their ability to act at distant site as well as locally, and to
propagate the functional antigens of their parent cell [1].
It was documented that MPs are implicated in modulation of
different stages of angiogenesis, although contradictory results
have been reported in the literature. Indeed, the different
responses evoked by MPs are dependent on their cellular origin,
stimulus of their generation and their concentration. MPs
shedding from endothelial cells (ECs) contain active proteases,
able to promote matrix degradation, but also the machinery to
generate them, presumably initiated by stimuli from environment.
Thus, they induce proteolysis during cell migration and three-
dimensional morphological organization during angiogenesis [2].
In contrast, another study showed that endothelial MPs are able to
impair in vitro angiogenesis by affecting all parameters of the
capillary network formation [3]. It has been shown that MPs
released by apoptotic lymphocytes inhibited in vitro and in vivo
angiogenesis, by enhancing ROS production, which leads
suppression of vascular cell survival, proliferation and migration
[4]. Furthermore, the same MPs are able to decrease NO
production via PI3K [5]. On the other hand, MPs generated from
human lymphocytes undergoing activation and apoptosis express
morphogen Shh (MPs
Shh+) at their surface and induce cell
differentiation [6]. Besides, these MPs have concomitant effect of
increasing NO production directly by Shh and PI3K pathways
and decreasing ROS production by a mechanism dependent on
PI3K and ERK cascades [7]. Moreover, we have observed that
MPs
Shh+ regulate multiple pathways related to in vitro angiogenesis,
mainly through the production of pro-angiogenic factors and up-
regulation of proteins involved in cell adhesion [8]. Thereby, the
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apoptotic lymphocytes are probably due to different stimulation at
their origin and also to the absence and presence of Shh,
respectively. Shh morphogen orchestrates several processes such as
cell proliferation, differentiation and angiogenesis [9]. Concerning
angiogenesis, it has been reported that activation of Shh cascade
evoked in vitro capillary-like structures formation and in vivo new
blood vessel generation [10–12]. Moreover, the effects promoted
by Shh affect modulation of VEGF and eNOS activities [13] and
involve PI3K/Akt pathway, which also belongs to intracellular
mechanism for endothelial NO release. As reported above, we
have shown that MPs
Shh+ are able to differentially regulate cell
events leading to in vitro angiogenesis [8]. To further validate the
observed effects on in vitro angiogenesis, here we used a mouse
model of hind limb ischemia, in order to investigate the efficacy of
MPs
Shh+ pro-angiogenic properties in neovascularization process
with respect to recovery of blood flow, vascular density,
implication of pathways which regulate NO production and
expression of key factors involved in angiogenesis. Understanding
the mechanism evoked by MPs in response to ischemia is essential
for the development of new therapeutic strategies for ischemic
cardiovascular diseases.
Materials and Methods
MP production
The human lymphoid CEM T cell line (ATCC, Manassas, VA)
was used for MP production. Cells were seeded at 10
6 cells/mL
and cultured in serum-free X-VIVO 15 medium (Lonza,
Walkersville, MD). MPs were produced as described previously
[6–8]. Briefly, CEM cells were treated with phytohemagglutinin
(5 mg/mL; Sigma-Aldrich, St. Louis, MO) for 72 h, then with
phorbol-12-myristate-13-acetate (20 ng/mL, Sigma-Aldrich) and
actinomycin D (0.5 mg/mL, Sigma-Aldrich) for 24 h. A superna-
tant was obtained by centrifugation at 750 g for 15 min, then at
1,500 g for 5 min to remove cells and large debris, respectively.
MPs from the supernatant were washed after serial centrifugation
steps (45 min at 14,000 g) and recovered in 400 mL NaCl (0.9%
w/v). Washing medium from the last supernatant was used as
control (vehicle). Determination of the amount of MPs was carried
out by measuring total MP-associated proteins, using the Bradford
method, and BSA (Sigma-Aldrich) for the standard curve, as
previously described [6–8].
Mouse Model of Hindlimb Ischemia
The University of Angers ethical committee approved the
present protocol. All animal studies were carried out using
approved institutional protocols and were conformed the Guide
for the Care and Use of Laboratory Animals published by US National
Institutes of Health (NIH Publication No. 85–23, revised 1996).
Four groups of male Swiss mice (Charles River Laboratories,
L’Arbresle, France), 6–8 weeks of age were treated, every three
days for 21 days: (i) mice receiving i.v. injection of vehicle (control
group, n=15); (ii) mice receiving i.v. injection of MPs (10 mg/mL
of blood) (n=13); (iii) mice receiving i.v. injection of MPs after
30 min of i.p. injection of cyclopamine (10 mg/kg) (Biomol
International, Plymouth Meeting, PA) (n=7); (iv) mice receiving
only i.p. injection of cyclopamine (n=6). We have taken in
consideration that total blood volume in the mouse is 6–8 ml of
blood/100 g of body weight [14]. The animals were housed in a
regulated environment with a constant ambient temperature of
24uC. They had free access to standard laboratory food and water.
Twenty four hours after the first injection, mice were
anesthesized with isoflurane and underwent surgery to induce
unilateral hindlimb ischemia. The ligation was performed on the
left femoral artery proximal to the bifurcation to the saphenous
and popliteal arteries as previously described [15,16]. After 7 and
21 days of ligature, blood flow was measured as described below.
At 21 day, mice were euthanized and tissues were sampled for
biochemical and histological analysis. The procedure followed in
the care and euthanasia of the study was in accordance with the
European Community standards on the care and use of laboratory
animals.
Quantification of neovascularization: Laser-Doppler
Blood Flow (LDBF) analysis
In order to provide a functional evidence of ischemia, laser
doppler perfusion imaging was performed in anesthetized mice, as
previously described [16]. Animals were settled on a heating plate
to maintain a stable cutaneous temperature in order to minimize
temperature variation throughout the experiments. Leg perfusion
was then measured using a Laser Doppler flow probe (PF 408,
Perimed, Stockholm, Sweden). Blood flow was recorded during
,3 min. At least 2 flow measurements were performed per leg.
Blood flow perfusion was expressed as a ratio of left (ischemic) to
right (non-ischemic) leg, as described by Limbourg et al. [17].
Vascular density
Vascular density, as an index of neovascularization, was
examined by counting the number of vessels taken from the
ischemic and non-ischemic limbs. Ischemic and non-ischemic
gastrocnemius muscles were dissected and embedded in Tissue-
Tek O.C.T (Sakura Finetek, Zoeterwoude, The Netherlands).
Cryosections (7 mm) were fixed (5 min at 220uC) in 100%
methanol, and saturated (1 h at room temperature) in blocking
buffer (5% non fat dry milk in PBS and 0.05% Tween 20). Fixed
and blocked tissue sections were incubated overnight at 4uC with
rat anti-mouse CD31 antibody (BD Biosciences, San Jose, CA).
After three washes, tissue sections were incubated (1 h at room
temperature) with goat anti-rat IgG fluorescein-conjugated
(Southern Biotech, Birmingham, AL) to identify vessels as
described by Limbourg et al. [17]. After final washes, sections
were mounted on glass slides. MRC-1024ES confocal equipment
mounted on a Nikon Eclipse TE 300 inverted microscope was
used for the optical sectioning of the tissue. Digital image
recording was performed using the Laser Sharp Software. Vessels
were quantified using ImageJ software and counted in at least four
randomly selected fields for each muscle section, and the mean
value for each section was calculated (magnification x40).
NO determination by electronic paramagnetic resonance
(EPR)
Detection of NO production was performed using a technique
with Fe
2+ diethyldithiocarbamate (DETC, Sigma) as spin trap.
After 21 days of ligation, animals were euthanized, aorta and both
ischemic and non-ischemic muscles were dissected and incubated
for NO production for 30 min in Krebs-Hepes buffer containing:
BSA (20.5 g/L), CaCl2 (3 mmol/L) and L-arginine (0.8 mmol/L).
NaDETC (3.6 mg) and FeSO4.7H2O (2.25 mg) were separately
dissolved under N2 gas bubbling in 10 mL volumes of ice-cold
Krebs–Hepes buffer. These were rapidly mixed to obtain
Fe(DETC)2 solution (0.4 mmol/L), which was used immediately
to incubate tissues for 45 min at 37uC. Then, tissues were
immediately frozen using liquid N2. NO measurement was
performed using a table-top x-band spectrometer Miniscope
(Magnettech, MS200, Berlin, Germany). Recording were made
at 77uK using a Dewar flask. Instrument setting was 10 mW of
MPs Promote Neovascularization
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of sweep time and 3 scans.
Western blot analysis
In each experiment, the aorta and the skeletal muscle from both
ischemic and non-ischemic leg were removed and frozen. Samples
were homogenized (Polytron; PRO250, Monroe, CT) and lysed.
Proteins were separated by SDS-PAGE and transferred onto
nitrocellulose membranes. Membranes were then saturated at
room temperature for 1 h in Tris buffer containing 1% Tween-20
and 5% BSA. Membranes were incubated overnight at 4uC with
one of the following primary monoclonal antibodies: anti-human
Shh, anti-human Ptc, anti-mouse Shh, anti-mouse Ptc (USBiolo-
gical, Swampscott, MA), anti-endothelial NOS (eNOS), anti-
caveolin-1 (BD Biosciences), anti-phospho-eNOS (Ser 1177), anti-
Akt, anti-phospho-Akt (Ser 473) (Cell Signaling, Beverly, MA), and
anti-VEGF (R&D systems, Minneapolis, MN). To visualize
protein gel loading, a polyclonal rabbit anti-actin antibody
(Sigma-Aldrich) was used at 1/2000 dilution. The membranes
were then washed at least three times in Tris buffer containing
0.05% Tween-20 and incubated for 1 h at room temperature with
the appropriate horseradish peroxidase (HRP)-conjugated second-
ary antibody (Amersham, Piscataway, NJ). The protein-antibody
complexes were detected by ECL-Plus Chemiluminescence kit
(Amersham) according to manufacturer’s protocol.
Quantitative real time RT-PCR analysis
In another set of experiments, the skeletal muscle from both
ischemic and non-ischemic legs were frozen and used to investigate
mRNA levels of 39 transcripts related to angiogenesis by
quantitative RT-PCR (q-PCR). q-PCR analyses were carried
out by Service Commun de Cytome ´trie et d’Analyses Nucle ´otidi-
ques from Angers University, using a Chromo 4
TM (Bio-Rad,
Hercules, CA) and SYBR Green detection. Primers were designed
using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi). Quantifications were realized according to the
DCt method and the relative gene-expression levels were normal-
ized using the geometric mean of three housekeeping genes as
previously described [18]. Data were expressed as a ratio of
ischemic on non-ischemic gene-level expression.
Statistical analysis
Data are represented as mean 6 SEM, n represents the number
of mice. Statistical analyses were performed by Mann-Whitney U-
tests (non-parametric). P,0.05 was considered to be statistically
significant.
Results
Enhanced recovery of blood flow after induction of
hindlimb ischemia in MPs
Shh+-treated mice
Serial blood flow measurements were performed sequentially in
the ischemic (left) and non-ischemic (right) hind limbs and were
analyzed by a LDBF image analyser and expressed as pseudoco-
lour images (Figure 1A). Hindlimb ischemia was induced by
ligating-excising the left femoral artery, and there was no
significant difference in the degree of post-operative ischemia
between groups (data not shown). Also, at day 7 after ligation,
there was no difference in blood flow in all groups. However, 21
days after surgery, ischemic-to-non-ischemic limb perfusion ratio
was modified and became evident in response to distinct
treatments (Figure 1B). In control mice, the recovery of blood
flow was not significantly different at day 7 and 21. In MPs
Shh+-
treated mice, the recovery of blood flow was significantly increased
after 21 days from ligation compared to day 7 (P,0.05).
Moreover, MPs
Shh+-treated mice showed a significant increase of
blood flow ratio (,1.4 fold) compared with the control group
(P,0.01). Interestingly, at day 21, treatment of mice with
cyclopamine prevented the enhancement of blood flow perfusion
evoked by MPs
Shh+ (P,0.01). It should be noted that cyclopamine
alone induced an increase of blood flow ratio when compared with
control group (Figure S1A). Together, these findings suggest that
MPs
Shh+ are able to improve blood perfusion and this effect is
directly mediated by Shh signalling, as illustrated by impaired
blood flow recovery in the presence of Shh pathway inhibitor.
MPs
Shh+ enhance vascular density after induction of hind
limb ischemia in mice
As illustrated in Figure 1C and 1D, after 21 days of ischemia,
MPs
Shh+ enhanced significantly the ratio of ischemic/non-
ischemic vascular density in hind limbs by ,62% compared with
vehicle-treated mice. This observation is consistent with the
findings that MPs
Shh+ improve foot reperfusion. In contrast,
cyclopamine failed to prevent the observed effects of MPs
Shh+ on
ischemic/non-ischemic vascular density ratio. Cyclopamine alone
did not induce significant changes in ischemic/non-ischemic limb
ratio of vessel number when compared to control group (Figure
S1B).
MPs
Shh+ stimulate endogenous Shh expression on mouse
ischemic muscle
We have evaluated whether exogenous or endogenous Shh is
involved in the effects of MPs
Shh+. Neither human Shh nor Ptc
were detected in skeletal muscles of mice after 21 days of MPs
Shh+
treatment (not shown). Moreover, although mouse Ptc expression
was not changed after MPs
Shh+ injection, mouse Shh expression
was enhanced in mice receiving MPs
Shh+ (P,0.01) (Figure 2A and
2B). Furthermore, at day 21, treatment of mice with cyclopamine
alone had no significant effect on both Ptc and Shh expressions
(Figure S1C and S1D), but it prevented the enhancement of mouse
Shh expression evoked by MPs
Shh+ (P,0.05) (Figure 2A and 2B).
MPs
Shh+ stimulate NO production and enhanced VEGF
expression in aorta
To determine whether MPs
Shh+ effects are not restricted to
ischemic area, but may target other vascular beds, we used aorta
as control. Firstly, we evaluated NO production in aorta. Aortic
rings from mice treated with either vehicle, MPs
Shh+ alone or
together with cyclopamine, preincubated with Fe(DETC)2,
exhibited an EPR feature of signal derived from NO-Fe(DETC)2
(data not shown). As shown in Figure 3A, MPs
Shh+ enhanced
significantly NO production in aorta compared to control
(P,0.05). Moreover, whereas cyclopamine alone did not modify
NO production (Figure 1SE), treatment with cyclopamine
prevented the increase of NO induced by MPs
Shh+ (P,0.05).
Next, we investigated the pathway involved in MPs
Shh+-induced
NO production. MPs
Shh+ treatment significantly enhanced
phosphorylation of eNOS and Akt on their activator sites (Ser
1177 and Ser 473, respectively), without affecting their expressions
(Figure 3B). Interestingly, blockade of Shh cascade by cyclopamine
suppressed the MPs
Shh+-induced activation of eNOS, but not that
of Akt. However, MPs
Shh+ treatment, as well as the administration
of cyclopamine, did not modify caveolin-1 expression. Moreover,
because VEGF plays a role in NO regulation, and VEGF-induced
angiogenesis is mediated by NO, we examined its expression.
MPs
Shh+ significantly promoted an increase of VEGF expression
(P,0.05) being inhibited by cyclopamine administration.
MPs Promote Neovascularization
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Shh+ induce Shh expression in mouse skeletal muscles. Histograms showing the effects of MPs
Shh+ on mouse Ptc (A)
and Shh (B) expressions. Values are expressed as a ratio of ischemic/non-ischemic protein expression in arbitrary units (A.U.) as mean 6 SEM
(n=5). **P,0.01 vs control group; #P,0.05 vs MPs
Shh+-treated mice.
doi:10.1371/journal.pone.0012688.g002
Figure 1. Quantitative evaluation of post-ischemic neovascularization after femoral artery ligature in mice. (A) Representative
pseudocolour laser Doppler blood flow (LDBF) images at day 7 and 21 following ligation of the left femoral artery in mice receiving vehicle (without
MPs
Shh+) (n=15), MPs
Shh+ alone (n=13), or with cyclopamine (n=7). (B) Histogram showing the quantification of the limb perfusion as a ratio of
blood flow reperfusion in ischemic and non-ischemic legs. (C) Representative immunofluorescence images of non-ligated (normal leg) and ischemic
leg of gastrocnemius muscle sections stained with CD31 from mice receiving vehicle (without MPs
Shh+), MPs
Shh+, and MPs
Shh+ with cyclopamine
during 21 days. (D) Quantification of number of CD31-stained vessels of gastrocnemius muscle sections from mice receiving vehicle (n=3), MPs
Shh+
(n=3), and MPs
Shh+ with cyclopamine (n=3). *P,0.05, **P,0.01. Data are expressed as ratio of ischemic to non-ischemic leg (mean 6 SEM).
doi:10.1371/journal.pone.0012688.g001
MPs Promote Neovascularization
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Shh+ enhance NO production and eNOS expression in
skeletal muscles
Consistent with the data obtained on aorta, skeletal muscles
from MPs
Shh+-treated mice exhibited a significant increase of NO
production (P,0.01) (Figure 4A). This effect was entirely reversed
after cyclopamine administration, indicating that MP-induced NO
release is sensitive to inhibition of Shh signaling (Figure 4A). It
should be noted that cyclopamine alone did not modify NO
production in skeletal muscles (Figure S1C).
MPs
Shh+ administration induced a significant increase in eNOS
expression (P,0.05), and its activation as shown by the eNOS
phosphorylation at Ser 1177 (Figure 4B). Moreover, expression of
caveolin-1, which plays a key role in negative regulation of
eNOS, was decreased in muscles from MPs
Shh+-treated mice
Figure 3. MPs
Shh+ stimulate NO production and VEGF expression in mice aorta. (A) Quantification of the amplitude of the NO-Fe(DETC)2
complex signals in mice aorta. Values are expressed as amplitude/mg of dried weight of aorta in arbitrary units (mean 6 SEM) (n=3 to 6). (B)
Histograms show the ratio of phosphorylation of eNOS Ser 1177 vs total eNOS, phosphorylation of Akt vs total Akt, and caveolin-1 and VEGF A
expressions. Immunoblots were quantified by densitometric analysis and normalized with either the full form of corresponding protein or with b-
actin (for caveolin-1 and VEGF A). Values are expressed in arbitrary units (A.U.) as mean 6 SEM (n=4). *P,0.05, **P,0.01 vs control group; #P,0.05
vs MPs
Shh+-treated mice.
doi:10.1371/journal.pone.0012688.g003
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was influenced by MPs
Shh+ administration. Also, VEGF expres-
sion was not affected by MPs
Shh+.W h e nS h hc a s c a d ew a s
pharmacologically inhibited, the effect induced by MPs
Shh+ on
eNOS expression was completely prevented, as well as its
activation; whereas caveolin-1 expression was not affected
compared to MPs
Shh+-treated mice. Concerning VEGF, cyclo-
pamine was able to significantly decrease its expression. On the
other hand, cyclopamine alone did not affect expression levels of
eNOS and VEGF (Figure S1F and S1G).
MPs
Shh+ regulate gene expression of angiogenic factors
in skeletal muscles
To investigate candidate targets of MPs
Shh+ implicated in
neovessels formation process, we have evaluated the mRNA levels
of 39 different angiogenic factors by q-PCR in skeletal muscles
(Table 1). MPs
Shh+ were able to enhance FGF2, FGF5 and VEGF
A, B and C mRNA levels, by a Shh-dependent mechanism for
FGF5 and VEGF A and by a Shh-independent mechanism for
FGF2 and VEGF B and C (Table 1). In addition, MPs
Shh+
decreased those of FLT-4, KDR, MMP-2, MT1-MMP and TSP-
1, that were reversed when Shh signalling was blocked (Table 1).
Also, MPs
Shh+ decreased expression of a5-integrin, E-selectin,
HGF, IGF-1, MCP-1, TGFb1, TGFb2 and VCAM-1 indepen-
dently of Shh pathway (Table 1).
Discussion
The present study is the first report showing the stimulatory
effects of MPs
Shh+ on in vivo neovascularization in post-ischemic
context and the resultant blood flow recovery in an experimental
model of hind limb ischemia. MPs
Shh+ treatment induces an
increase on Shh expression in ischemic skeletal muscle that was
prevented by the Shh inhibitor, cyclopamine. The effects evoked
by MPs
Shh+ involve NO pathway and differential modulation of
angiogenic factor expressions. However, not all the events
implicated on neovascularization and triggered by MPs
Shh+ are
modified in the presence of cyclopamine, indicating that either
some of the mechanisms involved are independent of Smo
receptor activation or other molecules carried by MPs play a role
in this phenomenon.
The formation of new blood capillaries is an important
component of pathological tissue repair in response to ischemia.
The development of an effective collateralization in the ischemic
zone involves angiogenesis, which is the sprouting of new
capillaries, and arteriogenesis, the development of arterial
structures from small preexisting collateral vessels [19]. The
present study demonstrates that MPs
Shh+ treatment stimulates
blood flow recovery in ischemic limbs after femoral artery ligation.
This effect is mediated directly by Shh as illustrated by the
abrogation of the capacity of MPs
Shh+ in increasing perfusion
in the presence of Shh antagonist, cyclopamine. In addition,
Figure 4. MPs
Shh+ activate eNOS pathway in skeletal muscles. (A) Quantification of the amplitude of the NO-Fe(DETC)2 complex signals in
muscles. Values are expressed as amplitude/mg of dried weight of skeletal muscles in arbitrary units (mean 6 SEM) (n=4 to 6). (B) Histograms
showing the effects of MPs
Shh+ on eNOS expression and phosphorylation on Ser 1177, caveolin-1 expression, Akt expression and phosphorylation on
Ser 473 and VEGF A expression. Values are expressed as a ratio of ischemic/non-ischemic protein expression in arbitrary units (A.U.) as mean 6 SEM
(n=4 to 9). *P,0.05, **P,0.01, ***P,0.001 vs control group; #P,0.05 vs MPs
Shh+-treated mice.
doi:10.1371/journal.pone.0012688.g004
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treatment with of MPs
Shh+, and this effect was prevented in the
presence of cyclopamine. These findings corroborate those
obtained by Pola et al. [20] showing that Shh has a regulator
role on angiogenesis during muscle regeneration after ischemia.
Although we cannot exclude an increase in NO-mediated
vasodilation induced by MPs
Shh+ (see below), it was demonstrated
that the stimulation of blood flow recovery was accompanied by an
increase in vascular density in ischemic hind limb muscles
suggesting that MPs
Shh+-induced stimulation of blood flow
reperfusion is due to neovessel formation. In contrast, Shh
pathway inhibition did not prevent MPs
Shh+-induced increase in
vascular density in skeletal muscles. It is plausible that, in the
presence of cyclopamine, non-functional vessels are formed as
suggested by the fact that vessels are present under these
conditions, but no flow recovery was detected.
Table 1. Effects of MPs
Shh+ on different mRNA expression on ischemic muscles.
mRNA
Ratio
(MPs vs CTL)
P value
(MPs vs CTL)
Ratio
(MPs+Cycl vs MPs)
P value
(MPs+Cycl vs MPs)
a5-integrin 0.52 ,0.05 1.03 ns
Ang-1 0.83 ns 1.87 ns
Ang-2 1.2 ns 0.80 ns
b3-integrin 1.06 ns 1.49 ns
E-selectin 0.29 ,0.05 2.03 ns
FGF1 1.21 ns 2.43 ns
FGF2 1.43 ,0.01 1.06 ns
FGF3 ND ND
FGF5 3.83 ,0.05 0.21 ,0.05
FGF7 0.88 ns 0.90 ns
FGF8 ND ND
FGF10 0.92 ns 2.32 ns
FGFR1 0.97 ns 1.18 ns
FGFR2 0.88 ns 0.32 ns
FLT-1 ND ND
FLT-4 0.48 ,0.05 3.41 ,0.05
HGF 0.29 ,0.05 1.00 ns
ICAM-1 0.73 ns 1.80 ns
IGF-1 0.30 ,0.05 1.02 ns
IL-1b ND ND
IL-6 ND ND
KDR 0.64 ,0.05 1.78 ,0.05
MCP-1 0.38 ,0.05 1.29 ns
MMP2 0.38 ,0.01 2.05 ,0.05
MT-1MMP 0.43 ,0.01 2.05 ,0.05
PECAM-1 1.01 ns 1.09 ns
SDF-1 0.67 ns 0.94 ns
TGFb1 0.58 ,0.05 1.27 ns
TGFb2 0.72 ,0.05 1.31 ns
Tie1 0.84 ns 1.67 ns
Tie2 0.88 ns 1.61 ns
TNFa ND ND
TSP-1 0.14 ,0.01 2.91 ,0.05
VCAM-1 0.68 ,0.05 1.69 ns
VE-cadherin 0.97 ns 0.95 ns
VEGF A 1.95 ,0.05 0.60 ,0.05
VEGF B 1.61 ,0.05 1.17 ns
VEGF C 1.32 ,0.05 1.01 ns
VEGF D 1.18 ns 0.75 ns
Value are expressed as ratio of mRNA expression ischemic/normal muscle from MPs
Shh+-treated mice versus control mice and from MPs
Shh+ + Cycl- versus MPs
Shh+-
treated mice (n=3 to 6). ND=No detected.
doi:10.1371/journal.pone.0012688.t001
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angiogenesis, data reported in the literature are contradictory
depending on the inhibition of either exogenous or endogenous
Shh. Indeed, Shh seems to exert a dualistic action in cardiac
ischemia in which high exogenous levels are able to foster tissue
repair and endogenous Shh seems to be deleterious [21]. In the
present study, we have observed that of MPs
Shh+ treatment did not
affect expression levels of both human (exogenous) Shh and Ptc
proteins; however, MPs
Shh+ treatment was able to induce mouse
(endogenous) Shh protein expression when compared to control
mice. These data suggest that after 21 days, MPs
Shh+ treatment
activates endogenous Shh pathway which seems to be beneficial in
ischemic muscles as suggested by Pola et al [20]. In addition,
although cyclopamine alone increased blood flow recovery at 21
days, this was not accompanied with changes in vascular density,
NO production, and expression or Ptc, Shh, eNOS and VEGF
suggesting that the cyclopamine effects on basal Shh pathway are
minimal.
It has been shown that Shh treatment induces an increase on
NO production via PI3kinase/Akt pathway in human ECs [22].
In the present study, MPs
Shh+ treatment was able to promote NO
production in non-ischemic area (aorta). In addition, in non-
ischemic area, MPs
Shh+ treatment activates both eNOS and Akt
pathways as reported in our previous study [7]. Indeed, MPs
Shh+
have been described able to activate the phosphatidylinositol 3-
kinase (PI3K)/Akt pathways leading to rapid and sustained
activation and enhanced expression of eNOS in ECs, aorta and
lungs [7]. Furthermore, the effects on eNOS activation were
sensitive to cyclopamine accordingly with our previous data [7]. In
the present study, we also found that, in aorta, MPs
Shh+ increased
expression of VEGF by a mechanism sensitive to cyclopamine, in
accordance with the effects evoked by MPs
Shh+ in ECs [8]. VEGF,
in addition to be pivotal angiogenic factor, plays an essential role
in NO regulation. Of note is that exogenous Shh protein has been
reported to induce eNOS and VEGF expressions in rat corpora
cavernosa [13]. Thus, Shh may act as a coordinator of crosstalk
between VEGF and NO and that eNOS and VEGF display
synergism in promoting NO production.
Regarding skeletal muscles, MPs
Shh+ induced an increase in NO
production through the activation of the Shh pathway. This was
associated with enhanced eNOS expression and its phosphoryla-
tion on the activator site. Concomitantly MPs
Shh+ decreased
caveolin-1 expression, which acts as negative regulator of eNOS
activity and NO production [23], but this occurs independently of
activation of Shh pathway. On the other hand, MPs
Shh+ did affect
neither Akt expression nor activation, indicating that, in skeletal
muscles, eNOS activation induced by MPs
Shh+ occurred by an
Akt-independent mechanism. In this way, it has been reported that
eNOS can be activated through a protein kinase C (PKC)-
sensitive, but PI3K/Akt-independent pathway [24,25]. Further
experiments are necessary to determine the kinase implicated in
the phosphorylation of eNOS evoked by MPs
Shh+. It should be
noted that, the fact that, in the presence of MPs
Shh+ plus
cyclopamine, eNOS phosphorylation and VEGF A expression
decreased to lower levels than basal levels. It might be possible that
the activation by MPs
Shh+ is needed to potentiate the inhibitory
effect of cyclopamine that cannot be observed under basal
conditions. Moreover, the above effects might not be linked to
the Shh pathway inhibition since cyclopamine alone had no effect
on these proteins (Figure S1F and 1G). We cannot distinguish
about the two hypotheses, nevertheless, the basal conclusion that
MPs
Shh+ induced an increase in NO production through the
activation of the Shh pathway still holds.
Moreover, our results suggest that MPs
Shh+ can modulate new
vessels formation either at transcriptional, and at post-transcrip-
tional level. Indeed, MPs
Shh+ strongly influenced the angiogenic
switch as revealed by the analysis of transcripts of a large number
of genes involved in angiogenesis. For example, they enhanced
expression of important angiogenic growth factors such as FGF2,
FGF5 and VEGF (A, B and C). Accordingly with the present data,
Giordano and coworkers [26] have described that intracoronary
gene transfer of FGF5 increases blood flow in an ischemic region
of the heart. Also, FGF2 induced stable collateral growth in
ischemic hind limb [27]. Moreover, it has been reported that
VEGF(s) expression in skeletal muscles results in the generation of
new blood vessels [28]. Surprisingly, the enhanced mRNA
expression of VEGF induced by MPs
Shh+ treatment was not
accompanied the corresponding increase of VEGF protein levels.
Several hypotheses can explain these results. On one hand, it is
plausible that expression of VEGF is delayed when compared to its
mRNA expression. On the other hand, it is possible that the
increase of translation to VEGF protein in ischemic/normal
muscles is performed at low levels which may be below the
threshold of detection for the antibody used in the present study.
Similar findings have been previously described in astrocytes by
others [29] and by our group [8]. Furthermore, MPs
Shh+
decreased expression of the potent antiangiogenic protein, TSP-
1. Consistent with the present study, Ridnour and collaborators
[30] have demonstrated that NO-induced angiogenesis is
regulated by the ability of NO to down-regulate TSP-1 expression.
Surprisingly, while mRNA levels of VEGFs were increased by
MPs
Shh+ treatment, expression of its receptors, FLT-4 and KDR,
was decreased. It is likely that a down-regulation of expression of
both types of receptors by MPs
Shh+ treatment or that expression of
VEGF receptors is delayed when compared to mRNA expression
of their ligands, as previously described in human ECs [8].
Nevertheless, several pro-angiogenic factors are over-expressed,
whereas anti-angiogenic factors are down-regulated suggesting
that MPs
Shh+ could induce angiogenesis through modulation of the
balance between pro- and anti-angiogenic factor expressions.
Furthermore, all effects of MPs
Shh+ treatment in mRNA level
expression were partially or totally reversed by inhibition of Shh
signalling, suggesting that a direct stimulation of vascular cells by
Shh associated with MPs is mandatory to favour formation of neo-
vessels.
In addition, MPs
Shh+ treatment decreased MT1-MMP and
MMP-2 expression levels by a Shh-dependent mechanism. These
findings may be explained by the fact that MMPs expressions and
activities are temporally regulated [31], acting mainly in the very
early phases of the initiation of angiogenesis. In fact, there are a
number of evidences showing that MMP-1 is present at the leading
tip of invading cells [32,33], and by its ability to activate MMP-2,
extends its degrading effect on extracellular matrix [32,34]. Once
neo-vessels are formed, the interaction between pericytes and the
newly formed endothelial tubes is accompanied by silencing of
MMPs activities which contributes to vascular stabilization [35].
All these regulated events may explain the decrease of their
expression after MPs
Shh+ treatment, at a stage at which
neovascularization has already occurred.
The remained question is by which mechanism(s) MPs
Shh+ are
able to induce endogenous Shh expression. It has been shown that
NO improves the effect of the ischemia induced in liver, kidney
and testicular tissue as measured by damage markers and
concomitantly increased Shh expression indicating that NO acts
via increase of Shh expression in ischemic tissue [36–38]. A similar
mechanism might occur in the present model. Indeed, MPs
Shh+
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Limitations of the study
We have previously shown that to generate MPs carrying Shh
from lymphocyte T cells, concomitant treatment with PHA +
PMA + Actinomycin D is needed [6]. Although the use of
chemicals in the culture to induce Shh expression could be limited
in order to avoid collateral/deleterious effects of MPs, it is clear
that MPs carrying Shh might represent a potential therapeutic tool
in pathologies associated with failed angiogenesis.
These data collectively show that MPs harbouring Shh may
contribute to blood vessel growth, maturation and stabilization in
a vascular network by reciprocally regulating the pro- and anti-
angiogenic factors through the increase of NO production, under
post-ischemic conditions. Thus, the present study highlights the
potential usefulness of MPs
Shh+ for therapeutic angiogenesis in
pathologies associated with peripheral ischemia.
Supporting Information
Figure S1 Effects of treatment of cyclopamine alone. (A)
Histograms showing the quantification of the limb perfusion at
day 7 and 21, as ratio of blood flow reperfusion in ischemic and
non-ischemic legs in control (CTL) (n=3) and cyclopamine
(CYCL)-treated group (n=3). *P,0.05 vs. CTL (B) Quantifica-
tion of number of CD31-stained vessels of gastrocnemius muscle
sections from mice receiving vehicle (CTL) or cyclopamine
(CYCL) alone. Data are expressed as ratio of ischemic to non-
ischemic leg (mean 6 SEM) (n=3). (C, D) Histograms showing
the effects of cyclopamine (CYCL) on Ptc (C) and Shh (D)
expressions. Values are expressed as a ratio of ischemic/non-
ischemic protein expression in arbitrary units (A.U.) as mean 6
SEM (n=3). (E) Quantification of the amplitude of the NO-
Fe(DETC)2 complex signals in muscles from control (CTL ) or
cyclopamine (CYCL)-treated mice. Values are expressed as
amplitude/mg of dried weight of skeletal muscles in arbitrary
units (mean 6 SEM) (n=3). (F, G) Histograms showing the effects
of cyclopamine (CYCL) on eNOS (F) and VEGF A (G)
expressions. Values are expressed as a ratio of ischemic/non-
ischemic protein expression in arbitrary units (A.U.) as mean 6
SEM (n=3).
Found at: doi:10.1371/journal.pone.0012688.s001 (0.76 MB TIF)
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